ardelyx
The Director, Development and Safety Quality provides independent quality oversight for clinical development, nonclinical, and pharmacovigilance activities at Ardelyx. This role ensures compliance with Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Pharmacovigilance Practices (GVP) while partnering with internal teams and external partners to maintain effective quality systems. The position involves driving inspection readiness, addressing compliance risks, and leading quality investigations and continuous improvement initiatives.
Headquarters
Waltham, Massachusetts, United States
Company Size
201-500 employees
Founded
2007
Ardelyx is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines for patients with unmet medical needs in gastrointestinal and cardiorenal diseases. The company markets IBSRELA (tenapanor) for irritable bowel syndrome with constipation (IBS-C) and XPHOZAH for chronic kidney disease with hyperphosphatemia, while also pursuing additional pipeline programs including chronic idiopathic constipation. Headquartered in Northern California, Ardelyx is committed to delivering novel-mechanism therapies that improve outcomes for patients with GI and kidney disorders.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ardelyx.
Vice President, Quality
Sabin Vaccine Institute
Associate Director, Quality Systems & Compliance (GCP/GLP/GVP)
Revolution Medicines
Associate Director GCP Quality
Kiniksa Pharmaceuticals
Director, GCP & GLP QA
Tango Therapeutics
Senior Manager, Quality Assurance GCP
Crinetics Pharmaceuticals
Associate Director, GCP QA
Mirum Pharmaceuticals